The stock's fall snapped a two-day winning streak.

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...